Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was -28.7% in Q3 FY26, the lowest of these four quarters. ROE, at 0.0%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE0.0%0.0%0.0%0.0%
ROIC0.0%0.0%0.0%−28.7%

Debt

Net debt is 11.58× a year’s EBITDA.

Net debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Net debt / EBITDA12.8×5.3×7.7×11.6×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+2 more TTM periods

0.00% 0.00% 0.00% 0.00%
ROA
0.00% 0.00% 0.00% 0.00%
ROIC
0.00% 0.00% 0.00% (28.66%)
Return on Tangible Assets
(78.60%) (112.84%) (86.05%) (19.20%)
Free Cash Flow per Share
(0.52) (1.05) (3.26) (0.92)
Free Cash Flow
(2.01) (7.20) (24.15) (47.78)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 12 Nov 2026